: Moderna’s RSV vaccine gets Breakthrough Therapy status


Moderna Inc. MRNA, -2.01% said Monday that the Food and Drug Administration granted the company’s experimental respiratory syncytial virus vaccine a Breakthrough Therapy Designation. Moderna said it plans to apply for approval in the first half of this year. The company’s stock has gained 18.7% over the past year, while the S&P 500 SPX, +0.25% is down 4.3%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleKey Words: Boris Johnson says Vladimir Putin threatened he could kill him in a minute ahead of Russia’s invasion of Ukraine
Next articleSpain consumer prices unexpectedly climb 5.8% in January on fuel prices


Please enter your comment!
Please enter your name here